Blog dedicated to the continuous education in Gynecology and Endocrinology

 

Gynecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy

Gadducci, Angiolo, Biglia, Nicoletta; Cosio, Stefania; Sismondi, Piero; Genazzani, Andrea – DGYE-2010-0002[487609]

BRCA1 and BRCA2 mutation carriers have a 54-85% and 45% lifetime risk of developing breast cancer, respectively, and a 18-60% and 11-27% lifetime risk of developing ovarian cancer, respectively. Oral contraceptive [OC]s significantly reduce the risk of ovarian cancer also in BRCA1/BRCA2 mutation carriers. more

Post to Twitter Post to Facebook

EFFECTS OF PRE- AND POSTMENOPAUSAL USE OF EXOGENOUS HORMONES ON RECEPTOR CONTENT IN NORMAL HUMAN BREAST TISSUE: A RANDOMIZED STUDY

G. Hallberg, U. Lundkvist, R. Bellocco, I. Persson, T. Naessén, C. Magnusson

Objective: To examine the effects on estrogen receptor alpha (ERα) and on progesterone receptor (PR) in normal human breast tissue after exposure to endogenous and exogenous hormones. more

Post to Twitter Post to Facebook

COMPARATIVE EFFECTS OF ORAL CONJUGATED EQUINE ESTROGENS AND MICRONIZED 17BETA-ESTRADIOL ON BREAST PROLIFERATION: A RETROSPECTIVE ANALYSIS

Wood CE, Clarkson TB, Chen H, Veenstra TD, Xu X, Scott L, Cline JM.

Menopause. 2008 Jul 18.

OBJECTIVE:: To evaluate the effects of oral conjugated equine estrogens (CEE) and micronized 17beta-estradiol (E2) on breast proliferation in a postmenopausal primate model. DESIGN:: Data from nine studies were analyzed retrospectively. The primary outcome measure was breast epithelial proliferation determined by immunolabeling for the Ki67 antigen. more

Post to Twitter Post to Facebook

ASSOCIATIONS BETWEEN SERUM TESTOSTERONE LEVELS, CELL PROLIFERATION AND PROGESTERONE RECEPTOR CONTENT IN NORMAL AND MALIGNANT BREAST TISSUE IN POSTMENOPAUSAL WOMEN

Marie Hofling, Lars Löfgren, Eva Von Schoultz, Kjell Carlström & Gunnar Söderqvist

Gestagens and progesterone receptors (PR) may play an important role in increased breast proliferation following combined estrogen-gestagen hormone therapy (HT). If androgens counteract this effect remains controversial. more

Post to Twitter Post to Facebook

USE OF THE LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM IN BREAST CANCER PATIENTS.

Trinh XB, Tjalma WA, Makar AP, Buytaert G, Weyler J, van Dam PA.

Fertil Steril. 2008 Jul;90(1):17-22.

OBJECTIVE: To study the recurrence of breast cancer among patients who were using the levonorgestrel-releasing intrauterine system (LNG IUS). DESIGN: A retrospective, controlled cohort analysis. SETTING: Six Belgian hospitals. more

Post to Twitter Post to Facebook

© International Society of Gynecological Endocrinology - Privacy Policy